Brind.

Astellas Pharma and VIR Biotechnology announced a collaboration to develop a PSMA-targeted T-cell engager.

1 report, 1 independent Updated Oct 1

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Astellas Pharma VIR Biotechnology

Keep exploring

The entities involved

Astellas Pharma
company
- Astellas Pharma, a Japan-based pharmaceutical company, was noted.Mon 12:38
VIR Biotechnology
biotech company
- Raymond James Financial reaffirmed a strong-buy rating and Morgan Stanley set a $25.00 price objective for VIR Biotechnology.Sat 07:36

Coverage

Newest first; wire copies grouped

Oct 1tickerreport.com